Rekombinanter KIR2DL2 (Lirilumab Biosimilar) Antikörper
Research Grade
Reaktivität: Human
FACS
Wirt: Human
Monoclonal
unconjugated
Recombinant Antibody
-
- Target Alle KIR2DL2 (Lirilumab Biosimilar) Produkte
- KIR2DL2 (Lirilumab Biosimilar)
- Antikörpertyp
- Recombinant Antibody
- Reaktivität
- Human
-
Wirt
-
Human
-
Klonalität
- Monoklonal
-
Konjugat
- Dieser KIR2DL2 (Lirilumab Biosimilar) Antikörper ist unkonjugiert
-
Applikation
- Flow Cytometry (FACS)
- Verwendungszweck
- Anti-KIR2DL2 (lirilumab biosimilar) mAb
- Produktmerkmale
- BMS-986015, IPH2102
- Aufreinigung
- Purified from cell culture supernatant by affinity chromatography
- Güteklasse
- Research Grade
- Isotyp
- IgG4
-
-
- Applikationshinweise
- Flow Cyt 1:100
- Kommentare
-
Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Lyophilized
- Rekonstitution
- Reconstitute with deionized water
- Buffer
- Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose is added as protectants before lyophilization.
- Lagerung
- -20 °C,-80 °C
- Informationen zur Lagerung
- Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
- Haltbarkeit
- 12 months
-
- Target
- KIR2DL2 (Lirilumab Biosimilar)
- Abstract
- KIR2DL2 (Lirilumab Biosimilar) Produkte
- Substanzklasse
- Biosimilar
- Hintergrund
- Synonyms: CD158b, CD158B1, NKAT-6, NKAT6, p58.2
- UniProt
- P43627
-
Sie sind hier:
